And fpfizer and getting ready fr the twoday meeting and waiting for the president to make a new proposal on tax reduction. And we will wait for the two components merck and pfizer. Are patent problems looming. After posting weak sales in north america and announcing two executives leaving the company. And you heard it here first, two firms buying hmas. And watch the fertilizer stock, because they are down after one of the Potash Companies drops. Slight sli above forecast and the revenues are shy of census, and fpfizer plans to go into three segments. Meanwhile, mercks q2 earnings were above estimates and the merck beats the earnings but profit is cut in the half. That is the repeating echo of the quarter and a lot of the names and in some cases blockbusters losing exclusivity and trying to fill the pipeline with stuff at the other end. That is the story of big pharma, and a pack of development and changing in recent months and years, carl. Of course, replacing off patent with whatever
Arcutis Biotherapeutics, Inc (NASDAQ:ARQT) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.
Revance Therapeutics, Inc (NASDAQ:RVNC) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.